ImmunityBio, Inc. is a commercial-stage biotechnology company that develops immunotherapies and cell therapies for the treatment of cancers and infectious diseases. The company's platforms are designed to activate both the innate and adaptive immune systems, utilizing natural killer (NK) cells, T cells, and memory T cells to create durable immunological memory. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an FDA-approved interleukin-15 (IL-15) superagonist complex used to treat non-muscle invasive bladder cancer. ImmunityBio's broader clinical pipeline includes off-the-shelf NK cell therapies, adenovirus-vectored vaccines, and fusion proteins targeting various solid tumors. The current corporate entity was formed through a 2021 reverse merger between the publicly traded NantKwest and the privately held ImmunityBio, combining their respective cell therapy and immunotherapy platforms.
